Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 2:07 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1777–1800 of 13,622 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dermatologic Disorders Clear all

Conditions: Psoriatic Arthritis
Interventions: AIN457 6 mg/kg i.v., Placebo, AIN457 3 mg/kg; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 381 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 31
States / cities: Birmingham, Alabama • Fountain Valley, California • Fullerton, California + 28 more

Conditions: Radiation Dermatitis
Interventions: StrataXRT, Calendula, Aquaphor; Device · Drug
Lead sponsor: Stratpharma AG; Industry
Eligibility: 18 Years and older
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Fabry Disease
Interventions: This is a non-interventional study; Other
Lead sponsor: Amicus Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Eagan, Minnesota

Conditions: Cardiomyopathy Due to Anthracyclines
Interventions: Allo-MSCs, Placebo; Biological
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 79 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 7
States / cities: Stanford, California • Gainesville, Florida • Miami, Florida + 4 more

Conditions: Metastatic Breast Cancer
Interventions: Writing Intervention; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Hyperhidrosis
Interventions: Ulthera System Treatment; Device
Lead sponsor: Ulthera, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Aventura, Florida

Conditions: Arthritis, Osteoarthritis Hand, Scleroderma, Systemic, Scleroderma, Diffuse, Rheumatoid Arthritis
Interventions: Custom Fabricated Splint; Other
Lead sponsor: Giovanna Fichera; Other
Eligibility: 18 Years to 100 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Troy, New York

Conditions: Atopic Dermatitis
Interventions: ADX-629 (Open-label); Drug
Lead sponsor: Aldeyra Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Bexley, Ohio

Conditions: Colorectal Neoplasms, Melanoma, Prostatic Neoplasms, Renal Cell Carcinoma, Neoplasms, Patients Who Have/Have Had Melanoma and Other Tumors
Interventions: CP-675,206 (Tremelimumab); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2023
U.S. locations: 5
States / cities: Los Angeles, California • Tampa, Florida • Ann Arbor, Michigan + 2 more

Conditions: Hermanski-Pudlak Syndrome, Colitis, Cytokines, Lymphocytes, Drug Evaluation
Interventions: Mesalamine, Infliximab, Corticosteroids, 6-Mercaptopurine, Tacrolimus, Adalimumab; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer
Interventions: sulindac, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Metastatic Breast Cancer
Interventions: Letrozole, Trastuzumab; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Boston, Massachusetts • St Louis, Missouri + 1 more

Conditions: Pain, Anxiety
Interventions: Hand-holding, Stress Ball; Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Metastatic Breast Cancer, Thyroid Dysfunction
Interventions: Triiodothyronine (T3); Drug
Lead sponsor: Aultman Health Foundation; Other
Eligibility: 18 Years to 105 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Canton, Ohio

Conditions: Breast Cancer
Interventions: Paclitaxel, Vinorelbine, Herceptin, Filgrastim; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Breast Cancer, Ovarian Cancer
Interventions: Psilocybin; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 21 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Aurora, Colorado

Conditions: Nephrogenic Systemic Fibrosis, Nephrogenic Fibrosing Dermopathy
Interventions: Not listed
Lead sponsor: Northwestern University; Other
Eligibility: Not listed
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Breast Cancer
Interventions: therapeutic autologous lymphocytes, Ifosfamide, carboplatin, and etoposide (ICE) regimen, Cyclophosphamide, Thiotepa, Carboplatin (CTC) or STAMP V (CTC), Leukapheresis, peripheral blood stem cell transplantation (PBSCT); Biological · Drug · Procedure
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Pyoderma Gangrenosum
Interventions: Xilonix; Biological
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Breast Cancer
Interventions: XELODA [capecitabine]; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004
U.S. locations: 35
States / cities: Little Rock, Arkansas • Deer Park, California • Greenbrae, California + 32 more

Conditions: Breast Cancer
Interventions: synthetic breast cancer peptides-tetanus toxoid-Montanide ISA-51 vaccine; Biological
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Breast Cancer
Interventions: EnVisio SmartClip, EnVisio™ Navigation System; Device
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Advanced Solid Tumor
Interventions: ARV-6723, Pembrolizumab, SOC; Drug
Lead sponsor: Arvinas Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 499 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 4
States / cities: New York, New York • Huntersville, North Carolina • San Antonio, Texas + 1 more

Conditions: Skin Lesion, Skin Abnormalities, Sebaceous Hyperplasia
Interventions: Nano-Pulse Stimulation Device; Device
Lead sponsor: Pulse Biosciences, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 5
States / cities: Sacramento, California • San Mateo, California • Chestnut Hill, Massachusetts + 2 more

Search by objective public record fields.

Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis

Retrospective Cohort Study Comparing a Novel Gel Dressing vs SoC in the Treatment of Radiation Dermatitis

Understanding Fabry Disease Therapy Choices Through the Eyes of the Patients

Stem Cell Injection in Cancer Survivors

Expressive Writing and Adjustment to Metastatic Breast Cancer

Histological Analysis Following Ulthera System Treatment for Hyperhidrosis

Novel Splinting Technique Using 3D Models

A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)

A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.

Medical Treatment of Colitis in Patients With Hermansky-Pudlak Syndrome

Sulindac in Preventing Breast Cancer in Women at High Risk for Breast Cancer

Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC

Patient Comfort During Dermatologic Procedures

Study of Euthyroid Hypothyroxinemia in Metastatic Breast Carcinoma

Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial

Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence

Nephrogenic Systemic Fibrosis (NSF): Analysis of Tissue Gadolinium Levels

Chemotherapy Followed by Peripheral Stem Cell Transplantation Plus Biological Therapy in Treating Women With Stage IV Breast Cancer

A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum

A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer

Vaccine Therapy in Treating Patients With Stage III or Stage IV Breast Cancer

Evaluation of EnVisio SmartClip for Intraoperative Localization of Breast Masses

A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors

Nano-Pulse Stimulation (NPS) in Sebaceous Hyperplasia